3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Hepatocellular
3
Rectal Neoplasms
2
Neoplasms
2
Glioma
2
Glioblastoma
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sinonasal Squamous Cell Carcinoma
1
Sarcoma
1
Radiation Injuries
1
Prostatic Neoplasms
1
Postoperative Complications
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Oropharyngeal Neoplasms
1
Melanoma
1
Lymphatic Metastasis
1
Lung Neoplasms
1
Low Anterior Resection Syndrome
1
Liposarcoma
1
Leiomyosarcoma
1
Hepatic Veno-Occlusive Disease
1
Head and Neck Neoplasms
1
Fatigue
1
Interventions
pembrolizumab
30
Paclitaxel
12
Carboplatin
10
Cisplatin
8
lenvatinib
7
Pemetrexed
5
belzutifan
4
Oxaliplatin
4
Gemcitabine
4
Fluorouracil
4
Capecitabine
4
patritumab deruxtecan
3
olaparib
3
Leucovorin
3
Albumin-Bound Paclitaxel
3
Acetaminophen
3
Levoleucovorin
2
Irinotecan
2
Histamine H2 Antagonists
2
Histamine Antagonists
2
Etoposide
2
Docetaxel
2
Dexamethasone
2
Cetuximab
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Surgical Procedures, Operative
×
30 days
×
Clear all
NCT03924856
2026-05-28
KEYNOTE-866
Merck Sharp & Dohme LLC
Phase 3
Completed
907 enrolled